Jonas Bouhlal, MSc, BSc^1,2,3*, Emmi Jokinen^3,4,5*, Petra Nygren^1,2,3*, Diogo Dias, MSc^1,2,3,6*, Aleksandr Ianevski^6*, Jay Klievink, M.Sc^2,3,5*, Hanna Lähteenmäki, MSc^1,2,3*, Essi Laajala, PhD^1,2,3*, Hanna Duàn, MSc^1,2,3*, Emmi Järvelä, MSc^7*, Helka Göös, PhD^7*, Matti Korhonen, MD, PhD^7,8*, Salomé Decombis^1,3,9*, Konstantin Matjusinski^1,2,3*, Mikko Myllymäki, MD, PhD^1,2,3, Maija Hollmén^10*, Khalid Saeed, PhD^2,3*, Dean Anthony Lee, MD, PhD¹¹, Tero Aittokallio, PhD^1,12,13,14*, Sara Gandolfi, MD, PhD^1,2,3*, Olli Dufva, MD, PhD^1,2,3,15* and Satu Mustjoki, MD, PhD^2,3,16

¹iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland
²Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
³Translational Immunology Research Program, University of Helsinki, Helsinki, Finland
⁴Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
⁵iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland
⁶Institute For Molecular Medicine Finland (FIMM), Helsinki, Finland
⁷Finnish Red Cross Blood Service, Helsinki, Finland
⁸Helsinki University Central Hospital Hospital for Children and Adolescents, Helsinki, FIN
⁹Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital, Nantes, France
¹⁰MediCity Research Laboratory, Department of Microbiology and Immunology, University of Turku, Turku, Finland
¹¹Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, OH
¹²Institute for Cancer Research, Department of Cancer Genetics, Oslo University Hospital, Oslo, Norway
¹³Centre for Biostatistics and Epidemiology (OCBE), Faculty of Medicine, University of Oslo, Oslo, Norway
¹⁴Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland
¹⁵Wellcome Sanger Institute, Hinxton, Cambridge, United Kingdom
¹⁶ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

Ammelie Svea Boje^1*, Anna Langner, PhD^1*, Carina Lynn Gehlert, PhD^1*, Carmen Reitinger, PhD^2*, Falk Nimmerjahn, PhD^2*, Eva Maria Murga Penas, PhD^3*, Sonja Bendig^4,5*, Guranda Chitadze, MD, PhD^4,5*, Monika Brüggemann, MD^5,6*, Katharina Diemer, MD^1*, Alexander Jochimsen^1*, Dorothee Winterberg, PhD^1*, Natalie Baum, PhD^1*, Steffen Krohn^1*, Thomas Valerius, MD^5,7*, Friedrich Stölzel^7*, Martin Gramatzki, MD¹, Katja Klausz, PhD^1,5*, Christian Kellner, PhD^8* and Matthias Peipp, PhD^1,5*

¹Division of Antibody-Based Immunotherapy, Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
²Division of Genetics, Department of Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
³Institute for Human Genetics, Christian-Albrechts-University Kiel and University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany, Kiel, Germany
⁴Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany
⁵Clinical Research Unit CATCH ALL (KFO 5010/1) funded by the Deutsche Forschungsgemeinschaft, Kiel, Germany
⁶Department of Internal Medicine II (Hematology/Oncology), University Hospital Schleswig-Holstein, Kiel, Germany
⁷Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel, Germany
⁸Division of Transfusion Medicine, Cell Therapeutics and Haemostaseology, LMU University Hospital, LMU Munich, Munich, Germany

Fuguo Liu^1,2*, Mubin Tarannum, PhD^1*, Yingjie Zhao^3*, Yiming J Zhang^2*, James Dongjoo Ham^4*, Kewen Lei^2*, Yuhao Qiang^2*, Xingyu Deng^1*, Maily Nguyen^1*, Dinh Khanhlinh^1*, Shaobo Yang^1*, Alaa Kassim Ali, PhD¹, Grace Caroline Birch, PhD^1*, Yuwen Yin^2*, Junru Cui^2*, Fangfeng Yuan^2*, Jerome Ritz, MD¹, Jianzhu Chen^2* and Rizwan Romee, MD^1,5,6

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Koch Institute For Integrative Cancer Research at MIT, Cambridge, MA
³Koch Institute For Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA
⁴Massachusetts Institute of Technology, Koch Institute For Integrative Cancer Research, Cambridge, MA
⁵Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Brigham & Women's Hospital, Boston, MA

Tom Leedom^1*, Basia Muz, PhD, MSc^2*, Kristann Magee^2*, Jayakumar Vadakekolathu, PhD^3*, Laura Arthur, PhD^4*, Melissa Tran, MSc^1*, Lena Luukkonen, BS^1*, Nitin Mahajan, PhD, MSc, MS^5*, Alexander Hamil, PhD^1*, John Muth, MSc^6*, Melissa M Berrien-Elliott, PhD^7*, Todd A Fehniger⁸, Sergio Rutella, MD, PhD, FRCPath⁹ and Jan K Davidson-Moncada, MD, PhD, MSc¹⁰

¹Wugen, San Diego
²Wugen, St Louis
³John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, United Kingdom
⁴Wugen, Saint Louis, MO
⁵Wugen, St Louis, MO
⁶Wugen, St. Louis, MO
⁷St Louis University, St Louis
⁸Department of Medicine, Division of Oncology, Washington University School of Medicine, Saint Louis, MO
⁹John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, ENG, United Kingdom
¹⁰Wugen, Washington, DC

Jieun Jang, MD, PhD^1,2, Mila Stanojevic^1*, Sara Piccinelli, MD, PhD^1*, Michal Sheffer, PhD^1*, Grace Caroline Birch, PhD^1*, Roman M. Shapiro, MD¹, Maximilian Stahl, MD³, John Koreth, MD, MBBS, PhD, DPhil¹, Catherine J. Wu, MD^4*, Robert J. Soiffer, MD⁵, Jerome Ritz, MD¹, Mubin Tarannum, PhD^4* and Rizwan Romee, MD¹

¹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Yonsei University College of Medicine, Seoul, South Korea
³Dana Farber Cancer Institute, Boston, MA
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁵Dana-Farber Cancer Inst., Boston, MA

Gordon Victor Hoffmann^1*, Adrian Gottschlich, MD^1,2,3,4*, Johannes Sam, PhD^5*, Samuel Gebhardt^5*, Lisa Rohrbacher, MSc^2,6*, Sayantan Nandi, PhD^1*, Emanuele Carlini^1*, Tobias Herold, MD^2,3, Michael von Bergwelt-Baildon, MD, PhD^2,4,7*, Stefan Endres, MD, Prof^1,3,8*, Marion Subklewe, MD^3,4,6,9, Peter Bruenker, PhD^5*, Christian Klein, PhD⁵ and Sebastian Kobold, MD^1,3,8*

¹Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany
²Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
³German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
⁴Bavarian Cancer Research Center (BZKF), Munich, Germany
⁵Roche Innovation Center Zürich, Pharma Research & Early Development, Zurich, Switzerland
⁶Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany
⁷germ, Munich, Germany
⁸Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
⁹Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany